Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses

Vaccine

Volumn 15, Issue 6-7, 1997, Pages 759-768

  Hodge, James W ^a   McLaughlin, Joanne P ^a   Kantor, Judith A ^a   Schlom, Jeffrey ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

ALVAC CEA; canarypox virus; immunogenicity; immunotherapy; vaccinia virus

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; RECOMBINANT VACCINE; VACCINIA VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CONTROLLED STUDY; FOWLPOX VIRUS; GENE EXPRESSION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TRANSGENE;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, NEOPLASM; AVIPOXVIRUS; CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; CELL LINE; CERCOPITHECUS AETHIOPS; CYTOTOXICITY TESTS, IMMUNOLOGIC; FEMALE; GENETIC VECTORS; HUMANS; IMMUNIZATION; IMMUNIZATION, SECONDARY; MICE; MICE, INBRED C57BL; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, SYNTHETIC; VACCINIA VIRUS; VIRUS REPLICATION;

EID: 0030988548     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(96)00238-1     Document Type: Article

References (34)

1. Paoletti, E., Tartaglia, J. and Cox, W.I. Immunotherapeutic strategies for cancer using poxvirus vectors. Ann. NY Acad. Sci. 1993, 690, 292-300
2. Kaufman, H., Schlom, J. and Kantor, J.A. Recombinant vaccinia virus expressing human carcinoembryonic antigen (CEA). Int. J. Cancer 1991, 48, 900-907
3. Kantor, J., Irvine, K., Abrams, S., Kaufman, H., DiPietro, J. and Schlom, J. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J. Natl Cancer Inst. 1992, 84, 1084-1091
4. Irvine, K., Kantor, J. and Schlom, J. Comparison of CEA-recombinant vaccinia virus, purified CEA, and an anti-idiotype antibody bearing the image of a CEA epitope in the treatment and prevention of CEA-expressing tumors. Vaccine Res. 1993, 2, 79-94
5. Earl, P.L. and Moss, B. Generation of recombinant vaccinia viruses. In: Current Protocols in Molecular Biology (Eds Ausubel, F.M., Brent, R., Kingston, R.E., Moore, D.D., Seidman, J.G., Smith. J.A. and Struhl, K.), John Wiley and Sons, New York, 1993, pp. 16.15.1-16.18.9
6. Cooney, E.L., McElrath, M.J. and Corey, L. et al. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Proc. Natl Acad. Sci. USA 1993, 90, 1882-1886
7. Etlinger, H.M. and Altenburger, W. Overcoming inhibition of antibody responses to a malaria recombinant vaccinia virus caused by prior exposure to wild type virus. Vaccine 1991, 9, 470-472
8. Kundig, T.M., Kalberer, C.P., Hengartner, H., Zinkernagel, R.M. Vaccination with two different vaccinia recombinant viruses: long-term inhibition of secondary vaccination. Vaccine 1993, 11, 1154-1158
9. Hamilton, J.M., Chen, A.P., Nguyen, B. et al. Phase I study of recombinant vaccinia virus (rV) that expresses human carcinoembryonic antigen (CEA) in adult patients with adenocarcinomas. ASCO Proc. 1994, 961
10. Tsang, K.Y., Zaremba, S., Nieroda, C.A., Zhu, M.Z., Hamilton, J.M. and Schlom, J. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J. Natl Cancer Inst. 1995, 87, 982-990
11. Conry, P.M., Saleh, M.N., Schlom, J. and Lobuglio, A.F. Breaking tolerance to carcinoembryonic antigen with a recombinant vaccinia virus in man. Am. Assoc. Cancer Res. 1995, (Abstract), 492
12. Taylor, J., Weinberg, R., Tartaglia, J. et al. Nonreplicating viral vectors as potential vaccines: recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins. Virology 1992, 187, 321-328
13. Taylor, J., Trimarchi, C. and Weinberg, R. et al. Efficacy studies on a canarypox-rabies recombinant virus. Vaccine 1991, 9, 190-193
14. Taylor, J., Tartaglia, J., Riviere, M. et al. Applications of canarypox (ALVAC) vectors in human and veterinary vaccination. Dev. Biol. Stand. 1994, 82, 131-135
15. Cadoz, M., Strady, A., Meignier, B. et al. Immunisation with canarypox virus expressing rabies glycoprotein [see comments]. Lancet 1992, 339, 1429-1432
16. Fries, L.F., Tartaglia, J., Taylor, J. et al. Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system. Vaccine 1996, 14, 428-434
17. Cox, W.I., Tartaglia, J. and Paoletti, E. Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-1 envelope glycoprotein. Virology 1993, 195, 845-850
18. Kent, S.J., Stallard, V., Corey, L. et al. Analysis of cytotoxic T lymphocyte responses to SIV proteins in SIV-infected macaques using antigen-specific stimulation with recombinant vaccinia and fowl poxviruses. AIDS Res. Hum. Retroviruses. 1994, 10, 551-560
19. Konishi, E., Pincus, S., Paoletti, E., Shope, R.E. and Wason, P.W. Avipox virus-vectored Japanese encephalitis virus vaccines: use as vaccine candidates in combination with purified subunit immunogens. Vaccine 1994, 12, 633-638
20. Ramshaw, I.A., Leong, K.H., Ramsay, A.J. and Boyle, D.B. Novel vaccine strategies for mucosal immunity using recombinant fowlpox viruses expressing cytokine genes. J. Cell. Biochem. 1995, (Abstract), 263
21. Taylor, J., Meignier, B., Tartaglia, J. et al. Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species. Vaccine 1995, 13, 539-549
22. Foon, K.A., Chakraborty, M., John, W.J., Sherratt, A., Kohler, H. and Bhattacharya-Chatterjee, M. Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine. J. Clin. Invest. 1995, 96, 334-342
23. Philip, R., Brunette, E., Philip, M. et al. Generation of tumor specific CTL using genetically modified antigen presenting cells: application in cancer immunotherapy. J. Immunother. 1995, 18, 127
24. Eades-Perner, A.M., Zimmerman, W. Carcinoembryonic antigen-transgenic mice: a model for tumor immunology. Tumour Biol. 1995, 15, 56-61
25. Perkus, M.E., Limbach, K. and Paoletti, E. Cloning and expression of foreign genes in vaccinia virus, using a host range selection system. J. Virol. 1989, 63, 3829-3836
26. Muraro, R., Wunderlich, D., Thor, A. et al. Definition by monoclonal antibodies of a repertoire of epitopes on carcinoembryonic antigen differentially expressed in human colon carcinomas versus normal adult tissues. Cancer Res. 1985, 45, 5769-5780
27. Fox, B.A., Spiess, P.J., Kasid, A. et al. In vitro and in vivo antitumor properties of a T-cell clone generated from murine tumor-infiltrating lymphocytes. J. Biol. Response Mod. 1990, 9, 499-511
28. Robbins, P.F., Kantor, J.A., Salgaller, M., Hand, P.H., Fernsten, P.D. and Schlom, J. Transduction and expression of the human carcinoembryonic antigen gene in a murine colon carcinoma cell line. Cancer Res. 1991, 51, 3657-3662
29. Wunderlich, J. and Shearer, G. Induction and measurement of cytotoxic T lymphocytes activity. In: Current Protocols in Immunology (Eds Colligan, J., Kruisbeek, D., Margulies, D., Shevach, E. and Strober, W.), John Wiley and Sons, New York, 1994, pp. 3.11.1-3.11.14
30. Mackett, M., Smith, G.L. and Moss, B. General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes. J. Virol. 1984, 49, 857-864
31. Egan, M.A., Pavlat, W.A., Tartaglia, J. et al. Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene. J. Infect. Dis. 1995, 171, 1623-1627
32. Mastrangelo, M.J., Maguire, H.C., McCue, P. et al. A pilot study demonstrating the feasibility of using intratumoral vaccinia injections as a vector for gene transfer. Vaccine Res. 1995, 4, 55-69
33. Wang, M., Bronte, V., Chen, P.W. et al. Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J. Immunol. 1995, 154, 4685-4692
34. Roth, J., Dittmer, D., Rea, D., Tartaglia, J., Paoletti, E. and Levine, A.J. p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge. Proc. Natl Acad. Sci. USA 1996, 93, 4781-4786